Navigation Links
PDL BioPharma Provides Third Quarter 2013 Revenue Guidance of $97 Million
Date:9/9/2013

INCLINE VILLAGE, Nev., Sept. 9, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the third quarter ending September 30, 2013, of approximately $97 million, as compared with actual revenue of $85 million for the third quarter of 2012, an approximate 14 percent increase.

(Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO )

The forecasted growth in revenues is driven by increased second quarter 2013 sales for Avastin®, Herceptin®, Lucentis®, Xolair®, Kadcyla®, Perjeta®, and Actemra® for which PDL receives royalties in the third quarter of 2013.  Sales of Avastin®, Herceptin®, Lucentis®, Xolair®, Perjeta®, and Kadcyla® (the Genentech Products) are subject to a tiered royalty rate for product that is made or sold in the United States and a flat royalty rate of three percent for product that is manufactured and sold outside of the United States (ex-US manufactured and sold).  The net sales thresholds and the applicable royalty rates for the Genentech Products are outlined below:   Genentech Products Made or Sold in US

Royalty RateNet sales up to $1.5 billion

3.0%Net sales between $1.5 billion and up to $2.5 billion

2.5%Net sales between $2.5 billion and up to $4.0 billion

2.0%Net sales exceeding $4.0 billion

1.0%Genentech Products Made and Sold ex-USNet sales

3.0%The third quarter royalty payment received from Genentech included royalties based on worldwide sales.

Revenue guidance for the third quarter of 2013 is net of an estimated payment due under our February 2011 settlement agreement with Novartis AG (Novartis). PDL pays to Novartis certain amounts based on net sales of Lucentis, made by Novartis, during calendar year 2011 and beyond. The amount paid is less than we receive in royalties on such sales.

Reported worldwide sales for Avastin increased approximately 13 percent in the second quarter of 2013 when compared to the same period in 2012.  Ex-U.S. manufactured and sold Avastin sales represented 38 percent of total Avastin sales in the second quarter of 2013 as compared with 29 percent in the second quarter of 2012.

Reported worldwide sales for Herceptin increased approximately 1 percent in the second quarter of 2013 when compared to the same period in 2012. Ex-U.S. manufactured and sold Herceptin sales represented 38 percent of total Herceptin sales in the second quarter of 2013 as compared with 37 percent in the second quarter of 2012.

Reported worldwide sales for Lucentis increased approximately 9 percent in the second quarter of 2013 when compared to the same period in 2012. All sales of Lucentis were from inventory produced in the United States.

Reported worldwide sales for Tysabri®, a Biogen Idec product, decreased approximately 1 percent for the second quarter of 2013 compared to the same period in 2012. Tysabri royalties are determined at a flat rate as a percentage of sales regardless of location of manufacture or sale.

The sales information presented above is based on information provided by PDL's licensees in their quarterly reports to the Company as well as from public disclosures made by PDL's licensees.

About PDL BioPharma
PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new income generating assets and maximizing value for its shareholders. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward-looking Statements
This press release contains forward-looking statements. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following:

  • The expected rate of growth in royalty-bearing product sales by PDL's existing licensees;
  • The relative mix of royalty-bearing Genentech products manufactured and sold outside the U.S. versus made or sold in the U.S.;
  • The ability of our licensees to receive regulatory approvals to market and launch new royalty-bearing products and whether such products, if launched, will be commercially successful;
  • The productivity of acquired income generating assets may not fulfill our revenue forecasts and, if secured by collateral, we may be undersecured and unable to recuperate our capital expenditures in the transaction;
  • Changes in any of the other assumptions on which PDL's projected royalty revenues are based;
  • The outcome of pending litigation or disputes, including PDL's current dispute with Genentech related to ex-U.S. sales of Genentech licensed products;
  • The change in foreign currency exchange rate;
  • Positive or negative results in PDL's attempt to acquire income generating assets; and
  • The failure of licensees to comply with existing license agreements, including any failure to pay royalties due.
  • Other factors that may cause PDL's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are discussed in PDL's filings with the SEC, including the "Risk Factors" sections of its annual report filed with the SEC. Copies of PDL's filings with the SEC may be obtained at the "Investors" section of PDL's website at www.pdl.com. PDL expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in PDL's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based for any reason, except as required by law, even as new information becomes available or other events occur in the future. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.


    '/>"/>
    SOURCE PDL BioPharma, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
    2. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
    3. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
    4. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
    5. Genesis Biopharma Announces Termination of Previously Announced Proposed Public Offering
    6. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
    7. S1 Biopharma Expands Focus to Include Male Sexual Health
    8. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
    9. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
    10. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
    11. Galena Biopharma, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/24/2016)... --   , Study met ... cleansing and superiority in , Excellent ... of the ascending colon   , ... Norgine B.V. today announced new positive data from the phase III ... versus standard 2 litre PEG with ascorbate. The study met both ...
    (Date:5/24/2016)... Zealand , May 24, 2016 ... informatics solutions for the healthcare sector, has been named the ... Zealand Hi-Tech Awards 2016. Dr Bruce Davey ... acknowledgement for our team.  It,s really good to be recognised ... healthcare internationally. Our products are used in 35 countries around ...
    (Date:5/24/2016)... , May 24, 2016 Celsion ... drug development company, today provided an update on ... escalating clinical trial combining GEN-1, the Company,s DNA-based ... treatment of newly-diagnosed patients with advanced ovarian cancer ... debulking surgery.  GEN-1 is an IL-12 DNA plasmid ...
    Breaking Medicine Technology:
    (Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... Southland ... line of classic American timber frame barn kits, which can be found on its ... inspired by historic American barn plans, and they highlight the craftsmanship of timber post ...
    (Date:5/27/2016)... ... May 27, 2016 , ... With over 60 percent of acute stroke survivors ... sustainable product to aid in the rehabilitation process has steadily increased. Ekso Bionics had ... with hemiplegia due to stroke. , Ekso Bionics has now received clearance from the ...
    (Date:5/27/2016)... ... May 27, 2016 , ... Beleza Medspa has initiated a new ... This is the first time that Coolsculpting is being used for for more than ... to ensure they meet the prescribed body-fat standard, measured by the circumference-based tape method. ...
    (Date:5/27/2016)... ... May 27, 2016 , ... With a team of ... food industries. Aside from its GMP accreditation, Validation Center is also a registered ... products, services and staff. , Validation Center is ISO17025 accredited and only offers ...
    (Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, Pfizer, and ... according to court documents and SEC filings. A jury has returned a ... American Optical Corporation, Case No. BC588866, Los Angeles County, California. The jury awarded ...
    Breaking Medicine News(10 mins):